Thyroid Associated Ophthalmopathy Clinical Trial
Official title:
Efficacy and Safety of Tocilizumab for Patients With Thyroid-associated Ophthalmopathy
This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.
Thyroid Associated Ophthalmopathy(TAO) is one of autoimmune orbital diseases characterized by enlargement of the extraocular muscles and increase in fatty or/and orbit connective tissue volume affecting the appearance and visual function of the eyes. In TAO pathogenesis, orbital fibroblasts are activated by autoantibodies against the thyrotropin receptor TSHR and the insulin-like growth factor-1 receptor. The fibroblasts then secrete interleukin-6 (IL-6), macrophage chemoattractant protein-1, and transforming growth factor-ß. In orbital preadipocyte fibroblasts, IL-6 increases expression of the thyrotropin receptor TSHR, and the orbital volume is relative to IL-6 mRNA expression. Thus, IL-6 may have several roles in the pathogenesis of TAO. Tocilizumab, a recombinant humanized IgG1 monoclonal antibody against IL-6 receptors, is FDA-approved for the treatment of rheumatoid arthritis, giant cell arteritis and juvenile idiopathic arthritis with a good toleration. The investigators carry this perspective cohort study to evaluate the efficacy of tocilizumab in TAO. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05110040 -
Multi-model Image of Immunosuppressive Agents in TAO
|
N/A | |
| Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03107078 -
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
|
Phase 4 | |
| Recruiting |
NCT04548284 -
Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO
|
Phase 3 | |
| Recruiting |
NCT03515863 -
Natural History and Risk Factors of TAO
|
||
| Not yet recruiting |
NCT06392906 -
Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)
|
Phase 3 | |
| Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
| Completed |
NCT00150111 -
Rituximab in the Treatment of Graves' Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT03110848 -
Effects of Atorvastatin in Graves' Orbitopathy (GO)
|
Phase 2 | |
| Recruiting |
NCT04662190 -
Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.
|
N/A | |
| Recruiting |
NCT05276063 -
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04919694 -
Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy
|
N/A | |
| Recruiting |
NCT03131726 -
Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S)
|
Phase 3 | |
| Completed |
NCT02766660 -
Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy
|
N/A | |
| Active, not recruiting |
NCT06269393 -
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
|
Phase 3 | |
| Not yet recruiting |
NCT03098225 -
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
|
Phase 4 | |
| Recruiting |
NCT05112211 -
Multi-model Image of Doxycycline in TAO
|
N/A |